Abstract
This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Cytotoxins / therapeutic use*
-
Disease Progression
-
Docetaxel
-
Drug Therapy, Combination
-
Estramustine / therapeutic use
-
Humans
-
Male
-
Mitoxantrone / therapeutic use
-
Neoplasms, Hormone-Dependent / drug therapy
-
Prognosis
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / secondary*
-
Taxoids / administration & dosage*
-
Taxoids / therapeutic use*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Hormonal
-
Cytotoxins
-
Taxoids
-
Docetaxel
-
Estramustine
-
cabazitaxel
-
Mitoxantrone